Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4342-4349

  Heinrich, Michael C ^a   Corless, Christopher L ^a   Demetri, George D ^a   Blanke, Charles D ^a   Von Mehren, Margaret ^a   Joensuu, Heikki ^a   McGreevey, Laura S ^a   Chen, Chang Jie ^a   Van Den Abbeele, Annick D ^a   Druker, Brian J ^a   Kiese, Beate ^a   Eisenberg, Burton ^a   Roberts, Peter J ^a   Singer, Samuel ^a   Fletcher, Christopher D M ^a   Silberman, Sandra ^a   Dimitrijevic, Sasa ^a   Fletcher, Jonathan A ^a  

^a R and D 19 ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ONCOPROTEIN; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; DNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CHO CELL; COMPARATIVE STUDY; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SITE DIRECTED MUTAGENESIS; STROMA CELL; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CRICETINAE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EXONS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STROMAL CELLS; SURVIVAL RATE; TRANSFECTION;

EID: 0642368571     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.190     Document Type: Article

References (41)

1. Fletcher C, Berman J, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459, 2002
2. Miettinen M, Lasota J: Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12, 2001
3. Lasota J, Wozniak A, Sarlomo-Rikala M, et al: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases. Am J Pathol 157:1091-1095, 2000
4. Lux ML, Rubin BP, Biase TL, et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791-795, 2000
5. Lasota J, Jasinski M, Sarlomo-Rikala M, et al: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53-60, 1999
6. Moskaluk CA, Tian Q, Marshall CR, et al: Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 18:1897-1902, 1999
7. Taniguchi M, Nishida T, Hirota S, et al: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297-4300, 1999
8. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
9. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
10. Corless CL, McGreevey L, Haley A, et al: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002
11. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA Activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
12. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
13. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
14. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
15. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001
16. Tuveson DA, Willis NA, Jacks T, et al: STI57I inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biologic and clinical implications. Oncogene 20:5054-5058, 2001
17. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
18. Van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 358:1421-1423, 2001
19. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
20. Rader A, Avery A, Wait CL, et al: Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors utilizing morphology, immunocytochemistry and mutational analysis of c-kit. Cancer 93:269-275, 2001
21. Choy YS, Dabora SL, Hall F, et al: Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Ann Hum Genet 63:383-391, 1999
22. Yarden Y, Kuang W-J, Yang-Feng T, et al: Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351, 1987
23. Bold G, Altmann KH, Frei J, et al: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (published erratum appears in J Med Chem 43:3200, 2000). J Med Chem 43:2310-2323, 2000
24. Green S, Weiss GR: Southwest Oncology Group standard response criteria, end point definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
25. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 78:427-434, 1983
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
28. Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744, 2002
29. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
30. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002
31. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591, 2002
32. Piccart M, Lohrisch C, Di Leo A, et al: The predictive value of HER2 in breast cancer. Oncology 61:73-82, 2001 (suppl)
33. Shah N, Nicoll J, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
34. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003
35. Rubin BP, Singer S, Tsao C, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001
36. Fletcher JA, Corless CL, Dimitrijevic S, et al: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:815, 2003 (abstr 3275)
37. Heinrich MC, Rubin BP, Longley BJ, et al: Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484-495, 2002
38. Gorre ME, Mohammed M, Ellwood K et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
39. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
40. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
41. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002